Market news

Earlier this week, BridgeBio Pharma reported peer-reviewed real-world data in Cardiology and Therapy showing that its ATTR cardiomyopathy therapy acoramidis was associated with lower early clinical worsening risk versus tafamidis in newly treated patients over a mean follow-up of 4.6 months. The study offers the first head-to-head, real-world comparison between approved transthyretin stabilizers, potentially strengthening the clinical and commercial positioning of acoramidis as Attruby in...

BridgeBio Pharma has delivered a strong share price run in recent years, and that kind of move naturally raises the question of whether the current valuation still lines up with the sales that sit behind the story. With fresh real world data around its acoramidis therapy now in the mix, investors are asking how much revenue power is realistically being priced into the stock today. Over the past 3 years the stock has gained 148.7%, which puts real pressure on the question of how much sales...

BridgeBio Pharma (NASDAQ:BBIO) expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies, President and CFO Thomas Trimarchi said during a Bernstein discussion. Trimarchi said the company’s strategy centers on developing medicines for gen

- In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinically significant 34% reduction in a composite of clinical worsening events (diuretic intensification, heart failure hospitalization, and mortality) versus tafamidis (p=0.046), supporting improved clinical stability of acoramidis over tafamidis - Acoramidis was also associated with a significant 43% r

On September 8, BridgeBio Oncology Therapeutics (NASDAQ:BBOT) released new clinical data for its lead KRASG12C inhibitor, BBO-8520, and used the moment to narrow its focus: the company is now prioritizing BBO-8520 paired with a checkpoint inhibitor in previously treated lung cancer patients, alongside combination work for its two earlier-stage assets, BBO-11818 and BBO-10203, in other […]

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

BridgeBio Pharma (BBIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Opportunities center on earlier genetic diagnosis, targeted FGFR3 therapies, long-acting CNP analogs and oral inhibitors. Developers can improve access, affordability, adherence and lifelong complication management across the US, Europe and Japan.Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Achondroplasia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The achondroplasia market across the seven major markets-the United States, G

PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one late-breaking oral presentation on the impact of oral infigratinib on medical complications in achondroplasia from PROPEL 3 will be shared at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026, taking place in

BridgeBio Pharma (NasdaqGS:BBIO) has entered a voluntary agreement with the U.S. government to expand access to its medicines and lower drug costs for American patients. The arrangement widens Medicaid access through a unique pricing and reimbursement model tailored to public health programs. The agreement keeps current Medicare Part D offerings in place without new pricing mandates on those products. Orphan indication drugs are excluded from future pricing commitments under this framework,...

Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.

PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences: 21st Annual Wells Fargo Healthcare Conference, Boston, MA: Wednesday, September 9 at 1:30 pm EDT2026 Cantor Global Healthca

BridgeBio Pharma has delivered a strong share price gain over the past three years, yet its current checks suggest the stock now looks closer to fairly valued than obviously cheap. With recent news around its ATTR-CM therapy acoramidis keeping expectations high, the question for investors is how much of that optimism is already reflected in the price. The stock is up 158.6% over three years, which sets a high bar for further returns after such a strong run. Progress on acoramidis, including...

- This voluntary agreement expands access for Medicaid patients to BridgeBio’s currently marketed medicine and lowers drug costs for Americans without jeopardizing innovation and sustainability in rare diseases - BridgeBio will continue to offer Attruby® via Medicare Part D without any future pricing mandates - The agreement has no impact on ForgingBridges®, a copay assistance program that helps reduce out-of-pocket costs to as little as $0 per month for qualifying patients PALO ALTO, Calif., Au

- The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis may improve cardiac structure and function with evidence of amyloid regression in a subset of patients

BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.

BridgeBio's 24% three-month rally faces a higher bar as Attruby growth and pipeline catalysts compete with valuation and execution risks.

PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two oral presentations and three posters on new acoramidis data in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared at the European Society of Cardiology (ESC) Congress 2026, taking place in Munich, Germany on August 28-31, 2026. The data wil

Motley Fool Press Release.

BridgeBio Pharma (NasdaqGS:BBIO) reports recent clinical and regulatory milestones across late-stage rare disease assets, including acoramidis, BBP-418, and encaleret. Acoramidis continues to show differentiated efficacy signals in ATTR-CM based on recent late-phase data and real-world findings. BBP-418 for LGMD2I/R9 and encaleret for ADH1 each receive Priority Review status, with BBP-418 positioned as a first potential therapy for its indication. Recent progress supports BridgeBio Pharma’s...

Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.

The company clearly has a winner on its hands with the recently approved Attruby.

- The transaction supports the evolution of the Company’s shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the pricing of a secondary offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The Compa

(Updates with the closing date in the second paragraph.) BridgeBio Pharma (BBIO) said Thursday it

PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the launch of a secondary public offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The Company is not selling any shares and will not receive any of the proceeds of the offering. William Blair, Goldman Sachs &

Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.

Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.

BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.